Success Metrics

Active Trials
1(17%)

Phase Distribution

Ph early_phase_1
1
17%
Ph not_applicable
4
67%
Ph phase_1
1
17%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
1(16.7%)
N/ANon-phased studies
4(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Other(5)

Detailed Status

unknown5
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (16.7%)
Phase 11 (16.7%)
N/A4 (66.7%)

Trials by Status

unknown583%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_1

MOv19-BBz CAR T Cells in FRa+ Cancers

NCT07116057
unknownearly_phase_1

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

NCT05225831
unknownnot_applicable

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

NCT04665063
unknownnot_applicable

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

NCT04666168
unknownnot_applicable

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

NCT04665076
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07116057Phase 1

MOv19-BBz CAR T Cells in FRa+ Cancers

Recruiting
NCT05225831Early Phase 1

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

Unknown
NCT04665063Not Applicable

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Unknown
NCT04666168Not Applicable

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Unknown
NCT04665076Not Applicable

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Unknown
NCT04610125Not Applicable

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6